Neovacs: Half-Year Report on the Liquidity Contract

Regulatory News:

Neovacs (Paris:ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of December 31, 2013:

• 25,939 shares
• €164,598.35

For the prior six month period (June 30, 2013), the corresponding figures were:

• 28,223 shares
• €151,698.16

About Neovacs
Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, whereas IFNa-Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr